In vitro activity of BRL 36650, a new penicillin.
Compared with four beta-lactam antibiotics and amikacin, BRL 36650 and BMY-28142 were the most active against 509 Enterobacteriaceae, including cefotaxime-resistant isolates and resistant laboratory mutants. BRL 36650 was more active than aztreonam, ceftazidime, and BMY-28142 against Acinetobacter spp., Pseudomonas aeruginosa, and other Pseudomonas spp.; all strains were inhibited by 2 micrograms/ml or less.
D000150:Acinetobacter / Q000187:drug effects; D000583:Amikacin / Q000494:pharmacology; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001398:Aztreonam / Q000494:pharmacology; D001419:Bacteria / Q000187:drug effects*; D000077723:Cefepime; D002442:Ceftazidime / Q000494:pharmacology; D002511:Cephalosporins / Q000494:pharmacology; D004755:Enterobacteriaceae / Q000187:drug effects*; D006801:Humans; D008826:Microbial Sensitivity Tests; D010403:Penicillin Resistance; D010406:Penicillins / Q000494:pharmacology*; D010878:Piperacillin / Q000494:pharmacology; D011549:Pseudomonas / Q000187:drug effects; D011550:Pseudomonas aeruginosa / Q000187:drug effects
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D010406:Penicillins; D000077723:Cefepime; D000583:Amikacin; C043286:foramidocillin; D002442:Ceftazidime; D001398:Aztreonam; D010878:Piperacillin